PT-886

中国北京、上海、广东松山湖，美国圣地亚哥 2024年11月06日，专注于肿瘤领域创新药物发现和开发的临床阶段生物技术公司凡恩世制药公司（Phanes Therapeutics）今天宣布，加州大学洛杉矶分校（UCLA）大卫·格芬医学院教授、国际知名的医学肿瘤专家Zev Wainberg教授加入公司的临床顾问委员会（CAB）。 凡恩世首席执行官王明晗博士表示：“我们非常高兴Zev Wainberg教授加入凡恩世临床顾问委员会。Wainberg 教授是消化道恶性肿瘤领域的顶尖医学肿瘤专家。他将与临床顾问委员会的其他顶尖专家一起，为凡恩世的三个临床项目提供宝贵的指导和建议。他丰富的专业知识和经验将进一步增强凡恩世在药物开发方面的实力，并提升公司为癌症患者提供创新疗法的能力。” Zev Wainberg教授介绍 Zev Wainberg教授, MD Wainberg博士是加州大学洛杉矶分校（UCLA）大卫·格芬医学院的学术肿瘤科医生，专注于消化系统恶性肿瘤。他目前担任UCLA消化道肿瘤项目的联合主任和胰腺癌中心的医学主任，兼任医学和外科学的职务。他的研究重点是消化系统癌症的转化研究，特别关注药物开发。此外，他还担任UCLA约翰逊综合癌症中心早期临床研究项目的主任。目前，他是超过25项针对消化系统癌症患者靶向治疗的临床试验的首席研究员。 凡恩世完整临床顾问委员会成员介绍请访问：https://www.phanesthera.com/about-us/cab/ 关于凡恩世制药 凡恩世制药（Phanes Therapeutics, Inc.）是一家临床阶段的生物技术公司，致力于肿瘤领域创新型药物的研究和开发。目前公司有三个处于临床阶段的项目，包括best-in-class单克隆抗体（mAb）项目PT199，以及两个first-in-class双特异性抗体（bsAbs）项目PT886和PT217。PT886和PT217都已获FDA孤儿药和快速通道资格认定。 凡恩世制药已经通过其专有技术平台PACbody®、SPECpair®和ATACCbody®建立了强大的研发管线，以开发新型生物制剂，解决癌症领域高度未满足的医疗需求的问题。PACbody®，是一种不需要蛋白质工程来构建双特异性抗体专有方法，从而使抗体分子保持具有卓越CMC特性的天然结构。SPECpair®技术平台，能利用传统的单克隆抗体制备工艺来生产具有天然IgG结构的双特异性抗体。ATACCbody®技术平台，是一种使用可调节活性的免疫肿瘤分子靶向实体瘤的专有技术，旨在最大限度地降低细胞因子风暴的风险。 关于更多凡恩世制药信息，请访问公司网站：www.phanesthera.com。 有关商务合作或媒体咨询，请分别联系bd@phanestx.com或media@phanestx.com。 推荐阅读： 凡恩世制药双抗PT886与KEYTRUDA®（帕博利珠单抗）联合治疗完成首例患者给药 凡恩世制药DLL3/CD47双抗PT217完成中国I期临床研究首例患者给药 凡恩世制药CD73单抗PT199完成中国I期临床研究首例患者给药 凡恩世DLL3/CD47双抗PT217获FDA第二个孤儿药认定，用于治疗神经内分泌癌 凡恩世制药claudin 18.2/CD47双抗PT886完成中国I期临床研究首例患者给药 凡恩世制药宣布与罗氏达成临床供药协议 凡恩世PT217获得FDA快速通道资格认定，用于治疗广泛期小细胞肺癌患者 凡恩世PT886获得FDA快速通道资格认定，用于治疗转移性claudin 18.2阳性胰腺癌患者 凡恩世制药双抗PT886临床试验申请获CDE批准 凡恩世宣布其三个专有技术平台获美国专利商标局授权注册商标 凡恩世制药DLL3/CD47双抗PT217临床试验申请获CDE受理 凡恩世制药claudin 18.2/CD47双抗PT886临床试验申请获CDE受理 凡恩世制药CD73单抗PT199临床试验申请获CDE受理 凡恩世制药宣布与默沙东公司达成临床试验合作与供药协议 国际著名肿瘤专家陆舜教授加入凡恩世临床顾问委员会 凡恩世制药宣布成立肿瘤临床顾问委员会 凡恩世制药宣布PT217双抗美国I期临床完成首例患者给药 全球首创！凡恩世宣布其Claudin 18.2/CD47双抗PT886美国I期临床完成首例患者给药 凡恩世与安斯泰来子公司Xyphos Biosciences达成研究合作协议 凡恩世宣布与百济神州达成临床供应协议，用于评估PT199与替雷利珠单抗的联合用药 专访凡恩世生物王明晗博士：创新照亮肿瘤治疗之路

SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that Zev Wainberg, MD, an internationally renowned medical oncologist and professor at David Geffen School of Medicine at UCLA, has joined the Company's Clinical Advisory Board (CAB). "We are excited to have Professor Wainberg joining our Clinical Advisory Board," said Ming Wang, PhD, MBA, Phanes' Chief Executive Officer. "Dr. Wainberg is a leading medical oncologist in gastrointestinal malignancies. He will join the other leading experts on our CAB to provide valuable guidance and advice on the three clinical programs at Phanes. His extensive expertise and experience will enhance Phanes' strength in drug development and ability to deliver innovative therapies for cancer patients." Biograph of Professor Zev Wainberg Zev Wainberg, MD Dr. Wainberg is an academic medical oncologist at the David Geffen UCLA School of Medicine specializing in gastrointestinal malignancies. He currently serves as the co-director of the GI oncology program and medical director of the Pancreas Cancer Center at UCLA with a joint appointment in medicine and surgery. His research focus is on translational research of GI cancers with a particular focus on drug development. He also serves as the director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center at UCLA. He is currently the principal investigator on over 25 clinical trials focused on targeted therapeutics in patients with gastrointestinal cancers. Full CAB information at . ABOUT PHANES THERAPEUTICS Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, PT199, the TWINPEAK study with PT886 and the SKYBRIDGE study with PT217. Both PT886 and PT217 are first-in-class bispecific antibodies and have been granted orphan drug designation as well as Fast Track designation by the FDA. The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer. For more information about Phanes Therapeutics, please visit . For business development or media inquiries, please contact [email protected] or [email protected], respectively. SOURCE Phanes Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED